Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses

By afschroeder • October 7, 2025

Foster L, Anderson LD Jr, Chung A, Chaulagain CP, Pettijohn E, Cowan AJ, Costello C, Larson S, Sborov DW, Shain KH, Silbermann R, Voorhees P, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin TS, Badros A. Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses. Blood Cancer J. 2025 Oct 6;15(1):154. doi: 10.1038/s41408-025-01355-0. PMID: 41053004.

Tags: Hematology/Oncology, Publications

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma

Sullivan RJ, Tsai KK, Pavlick AC, Buchbinder EI, Agarwala SS, Ribas A, Jansson J, Rossiter G, Olszanski AJ. Phase 1b Study of Tovorafenib, Plozalizumab or[...]

ASCO State of Cancer Care in America Special Report 2025: Access to Cancer Clinical Trials in the United States

Balogh EP, Levit LA, Unger JM, Accordino MK, Chism DD, Kirkwood MK, Parsons HM, Patel MI, Peppercorn JM, Polite BN, Sedrak MS, Sharma P, Subbiah[...]

Inflammation and dimensions of fatigue in women with early stage breast cancer: A longitudinal examination

Bower JE, Radin A, Ganz PA, Irwin MR, Cole SW, Petersen L, Asher A, Hurvitz SA, Crespi CM. Inflammation and dimensions of fatigue in women[...]